Studies on the combined treatment using etanercept and ultraviolet B for patients with moderate to severe psoriasis vulgaris
- Conditions
- Psoriasis vulgaris (Plaque-Typ)MedDRA version: 9.1Level: LLTClassification code 10050576Term: Psoriasis vulgaris
- Registration Number
- EUCTR2008-000106-37-DE
- Lead Sponsor
- Klinik für Dermatologie und Allergologie der RUB, St. Josef Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Authorised-recruitment may be ongoing or finished
- Sex
- All
- Target Recruitment
- Not specified
-Patients eligible for etanercept treatment according to SPC and local guidelines and
regulations
- Patients ages 18 or older
-Psoriasis vulgaris (Plaque-Typ)
-given indication of therapy with Etanercept
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range
-Pregnancy or nursing mothers
-Patients with severe cardio-respiratory insufficiency
-known photodermatosis (for example: urticaria solaris)
-known genodermatosis with increased UV-sensitivity
-intake of photosensitizing drugs
-allergy to local anesthetics
-anamnesis of wound healing disorders or keloids
-skin cancer in the presence or in the past
-systemic immunsuppressive therapy
- significant UV-exposure 3 months before the beginning of the study
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method